Spyryx's SPX-101 improves lung function in Phase II CF trial

Spyryx Biosciences Inc. (Durham, N.C.) said high-dose SPX-101 given via a portable nebulizer led to a placebo-adjusted increase in percent predicted forced expiratory

Read the full 238 word article

User Sign In